Cover Image
市場調查報告書

全球院內感染性肺炎市場上開發平台分析(Tedizolid phosphate,Ceftolozane/Tazobactam,Ceftazidime/Avibactam,Amikacin Inhale,Plazomicin,Synflorix疫苗)-產業分析·市場規模·佔有率·成長與趨勢與預測

Pipeline Analysis of Hospital Acquired Pneumonia Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020

出版商 Transparency Market Research 商品編碼 312133
出版日期 內容資訊 英文 74 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全球院內感染性肺炎市場上開發平台分析(Tedizolid phosphate,Ceftolozane/Tazobactam,Ceftazidime/Avibactam,Amikacin Inhale,Plazomicin,Synflorix疫苗)-產業分析·市場規模·佔有率·成長與趨勢與預測 Pipeline Analysis of Hospital Acquired Pneumonia Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020
出版日期: 2014年09月01日 內容資訊: 英文 74 Pages
簡介

院內感染性肺炎又被稱之為醫療相關肺炎或院內肺炎,是在醫院內傳染的疾病。和地區性傳染型肺炎不同,院內感染型肺炎主要是由多重抗藥性微生物所引起。全球院內感染性肺炎藥物市場在全球性院內肺炎得病率的增加推動下促進了成長。

本報告提供全球院內感染性肺炎市場現況與展望,詳細調查治療院內感染肺炎的後期候補藥及臨床試驗初期階段產品藥物,為您彙整市場推動與阻礙成長要素及市場機會分析,主要的6種後期(第三階段)藥物及10種初期(第一階段,第二階段)候補藥的調查及預測,以及主要企業簡介等資訊。

第1章 簡介

  • 調查的說明
  • 市場區隔
  • 調查手法
  • 簡稱
  • 前提

第2章 摘要整理

  • 院內感染性肺炎第三階段候補藥,市場佔有率,2020年(以金額為準%)

第3章 市場概要

  • 簡介
    • 院內肺炎的種類
      • 細菌性肺炎
      • 病毒性肺炎
    • 院內感染性肺炎的流行病學
    • 院內感染性肺炎的診斷
    • 院內感染性肺炎的治療
  • 市場動態
    • 推動市場成長要素
      • 感染性細菌強化了抗藥性增加了院內感染性肺炎的機會
      • 低·中所得國的缺乏效率消毒及不衛生條件增加院內感染性肺炎的得病率
    • 阻礙市場成長要素
      • 政府為了降低院內感染性肺炎而詳細調查住院費用保險
    • 市場機會
      • 院內肺炎市場上疫苗的潛力未來
      • 研究肺炎球菌以外的致病原因之疫苗開發的可能性
  • 活動影響分析
  • 價值鏈分析
  • 波特的五力分析
  • 院內感染性肺炎主要藥物及疫苗的市場分析
    • 院內肺炎市場上領導品牌藥物及疫苗的銷售趨勢(一百萬美元)

第4章 院內感染性肺炎,開發平台分析

  • 簡介
  • 後期(第三階段)
    • Tedizolid phosphate
    • Ceftolozane/Tazobactam
    • Ceftazidime/Avibactam
    • Amikacin Inhale
    • Plazomicin
    • Synflorix疫苗
  • 初期(第一階段,第二階段)
    • BAL30072
    • MEDI4893
    • AR-301或KBSA301
    • AR-101(或KBPA101)和AR-104(或KBPA104)
    • AR-201(或KBRV201)
    • AR-401(或KBAB401)
    • ME1100
    • GSK 2189242A
    • V114
    • IC43

第5章 全球院內感染性肺炎市場上開發平台的檢討,各地區

  • 簡介
  • 北美
  • 歐洲
  • 亞太地區
  • 其他地區

第6章 建議

  • 生物製藥的研究開發
  • 合併,收購,策略敵人協定

第7章 企業簡介(企業概要,業績概要,產品系列,產業策略,最近的動向)

  • Achaogen, Inc.
  • Aridis Pharmaceuticals
  • AstraZeneca plc
  • Cubist Pharmaceuticals, Inc.
  • Meiji Seika Pharma
  • Merck & Co. Inc.
  • Sanofi
  • GlaxoSmithKline, Inc.
  • Valneva SE
目錄

Hospital-acquired pneumonia also called as healthcare associated pneumonia or nosocomial pneumonia is acquired in hospital premises. Unlike community acquired pneumonia hospital acquired pneumonia is mainly caused due to multidrug resistant microorganisms. The report analyzes the market for late stage candidates for treatment of nosocomial pneumonia, and also provides a detailed review of drugs in early stages of clinical trials. The report studies and estimates market for six late stage along with an elucidation of ten early stage candidates for nosocomial pneumonia treatment.

Phase III candidates include tedizolid phosphate, ceftolozane/tazobactam, ceftazidime/avibactam, amikacin inhale, plazomicin and synflorix vaccine. Market for each of the investigational drugs is estimated based on current anti-microbial efficiency, historic market trend and patents of drugs from similar class, manufacturing and marketing licenses, along with competition from commercialized and pipeline drugs. Hospital acquired pneumonia drugs market for phase III candidates has been estimated from the expected year of launch till 2020. The hospital acquired pneumonia drugs market report also gives a brief review of the various drugs commercially available for treating hospital acquired pneumonia. Historic market revenue of these drugs from 2011 to 2013 has also been included. Market forecast mainly rests on a detailed event impact analysis, which considers historic as well as anticipated events which impact the market in varying degrees.

Global market for hospital acquired pneumonia drugs is mainly driven by the increasing prevalence of nosocomial infections across the globe. To illustrate this fact, the report includes a statistical comparison of the prevalence of nosocomial infections in various developed and developing countries. Geographical trend of hospital acquired pneumonia drugs market, is explains with a brief regulatory approval process, along with expected time frame for drug launch in various countries. These trends have been explained for geographical regions including North America, Europe, Asia Pacific and Rest of the World.

To gain a complete market understanding, Porters Five Force's analysis, and value chain analysis has also been included in the hospital acquired pneumonia drugs market report. The report also explains key market drivers, restraints, opportunities in the hospital acquired pneumonia drugs market. Diagnosis, treatment, and epidemiology of hospital acquired pneumonia gives a clinical overview of the disease and current modes of disease management. Relevant recommendations have been suggested for designing successful market strategies for competing in the market.

Hospital acquired pneumonia drugs market report also includes company profiles of key market players. These include Achaogen, Inc., Aridis Pharmaceuticals, AstraZeneca plc, Cubist Pharmaceuticals, Inc., Meiji Seika Pharma Co. Ltd., Merck & Co. Ltd., Sanofi, GlaxoSmithKline, Inc., and Valneva SE. All of these players are profiled considering company overview, financial overview, product portfolio, business strategies, and recent developments.

The research methodology was based on primary as well as secondary research. Interviews and discussions with a wide range of key industry participants and opinion leaders revealed real time market scenario. This primary research represented the bulk of the research efforts, which was further supplemented by extensive secondary research. A review of key players' product literature, annual reports, and press releases supports the market forecast analysis. The 74 page report explains various market dynamics in 4 tables and 17 figures and charts.

Table of Contents

Chapter 1 Introduction

  • 1.1 Report Description
  • 1.2 Market Segmentation
  • 1.3 Research Methodology
    • 1.3.1 Secondary Research
    • 1.3.2 Primary Research
  • 1.4 List of Abbreviations
  • 1.5 Assumptions

Chapter 2 Executive Summary

  • 2.1.1 Hospital Acquired Pneumonia Phase III Candidates, Market Share, 2020 (Value %)

Chapter 3 Market overview

  • 3.1 Introduction
    • 3.1.1 Types of Nosocomial Pneumonia
      • 3.1.1.1 Bacterial pneumonia
      • 3.1.1.2 Viral pneumonia
    • 3.1.2 Epidemiology of hospital acquired pneumonia
    • 3.1.3 Diagnosis of hospital acquired pneumonia
    • 3.1.4 Treatment of hospital acquired pneumonia
  • 3.2 Market Dynamics
    • 3.2.1 Market Drivers
      • 3.2.1.1 Rising drug resistance among infectious microorganisms increasing chances of hospital acquired infections
      • 3.2.1.2 Inefficient sterilization and unhygienic conditions in low and middle income countries increasing prevalence of hospital acquired infections
        • 3.2.1.2.1 Prevalence of hospital acquired infections in developed and developing countries
    • 3.2.2 Market Restraints
      • 3.2.2.1 Government scrutinizing hospital policies to curb hospital-acquired infections
    • 3.2.3 Market Opportunities
      • 3.2.3.1 Promising future for vaccines in the nosocomial pneumonia market
      • 3.2.3.2 Potential for research in vaccine development for causative agents other than S. pneumonia
  • 3.3 Event Impact Analysis
    • 3.3.1 Event Impact Analysis: Hospital Acquired Pneumonia Market
  • 3.4 Value Chain Analysis
    • 3.4.1 Value Chain Analysis
  • 3.5 Porter's Five Forces Analysis for the Global Hospital Acquired Pneumonia Drugs Market
    • 3.5.1 Bargaining Power of Suppliers
    • 3.5.2 Porter's Five Forces Analysis: Global Hospital Acquired Pneumonia Market
    • 3.5.3 Bargaining Power of Buyers
    • 3.5.4 Threat of Substitutes
    • 3.5.5 Threat of New Entrants
    • 3.5.6 Competitive Rivalry
  • 3.6 Market Analysis of Major Drugs and Vaccines for Hospital Acquired Pneumonia
    • 3.6.1 Revenue trend of major branded drugs and vaccines in nosocomial pneumonia market (USD Million)

Chapter 4 Hospital Acquired Pneumonia, Pipeline Analysis

  • 4.1 Introduction
  • 4.2 Late Stage (Phase III)
    • 4.2.1 Tedizolid phosphate
      • 4.2.1.1 Global Tedizolid Phosphate Market Revenue, 2017 - 2020 (USD million)
    • 4.2.2 Ceftolozane/Tazobactam
      • 4.2.2.1 Global Ceftolozane/Tazobactam Market Revenue, 2017 - 2020 (USD million)
    • 4.2.3 Ceftazidime/Avibactum
      • 4.2.3.1 Global Ceftazidime/Avibactam Market Revenue, 2017 - 2020 (USD Million)
    • 4.2.4 Amikacin Inhale
      • 4.2.4.1 Global Amikacin Inhale Market Revenue, 2016 - 2020 (USD Million)
    • 4.2.5 Plazomicin
      • 4.2.5.1 Global Plazomicin Market Revenue, 2017 - 2020 (USD Million)
    • 4.2.6 Synflorix Vaccine
      • 4.2.6.1 Global Synflorix Market Revenue, 2012 - 2020 (USD Million)
  • 4.3 Early Stage (Phase I and II)
    • 4.3.1 BAL30072
    • 4.3.2 MEDI4893
    • 4.3.3 AR-301 or KBSA301
    • 4.3.4 AR-101 (or KBPA101) and AR-104 (or KBPA104)
    • 4.3.5 AR-201 (or KBRV201)
    • 4.3.6 AR-401 (or KBAB401)
    • 4.3.7 ME1100
    • 4.3.8 GSK 2189242A
    • 4.3.9 V114
    • 4.3.10 IC43

Chapter 5 Global Pipeline Review of Hospital Acquired Pneumonia Drugs Market, by Geography

  • 5.1 Introduction
  • 5.2 North America
  • 5.3 Europe
  • 5.4 Asia Pacific
  • 5.5 Rest of the World

Chapter 6 Recommendations

  • 6.1 Research and development for biological drugs
  • 6.2 Mergers, acquisitions and strategic agreements

Chapter 7 Company Profiles

  • 7.1 Achaogen, Inc.
    • 7.1.1 Company Overview
    • 7.1.2 Financial Overview
    • 7.1.3 Product Portfolio
    • 7.1.4 Business Strategies
    • 7.1.5 Recent Developments
  • 7.2 Aridis Pharmaceuticals
    • 7.2.1 Company Overview
    • 7.2.2 Financial Overview
    • 7.2.3 Product Portfolio
    • 7.2.4 Business Strategies
    • 7.2.5 Recent Developments
  • 7.3 AstraZeneca plc
    • 7.3.1 Company Profile
    • 7.3.2 Financial Overview
    • 7.3.3 Product Portfolio
    • 7.3.4 Business Strategies
    • 7.3.5 Recent Developments
  • 7.4 Cubist Pharmaceuticals, Inc.
    • 7.4.1 Company Overview
    • 7.4.2 Financial Overview
    • 7.4.3 Product Portfolio
    • 7.4.4 Business Strategies
  • 7.5 Meiji Seika Pharma Co. Ltd.
    • 7.5.1 Company Overview
    • 7.5.2 Financial Overview
    • 7.5.3 Product Portfolio
    • 7.5.4 Business Strategies
    • 7.5.5 Recent Developments
  • 7.6 Merck & Co. Inc.
    • 7.6.1 Company Overview
    • 7.6.2 Financial Overview
    • 7.6.3 Product Portfolio
    • 7.6.4 Business Strategies
    • 7.6.5 Recent Developments
  • 7.7 Sanofi
    • 7.7.1 Company Overview
    • 7.7.2 Financial Overview
    • 7.7.3 Product Portfolio
    • 7.7.4 Business Strategies
    • 7.7.5 Recent Developments
  • 7.8 GlaxoSmithKline, Inc.
    • 7.8.1 Company Overview
    • 7.8.2 Financial Overview
    • 7.8.3 Product Portfolio
    • 7.8.4 Business Strategies
    • 7.8.5 Recent Developments
  • 7.9 Valneva SE
    • 7.9.1 Company Overview
    • 7.9.2 Financial Overview
    • 7.9.3 Product Portfolio
    • 7.9.4 Business Strategies
    • 7.9.5 Recent Developments

List of Figures

  • FIG. 1 Hospital Acquired Pneumonia: Drug Pipeline
  • FIG. 2 Hospital Acquired Pneumonia Phase III Candidates, Market Share, 2020 (Value %)
  • FIG. 3 Value Chain Analysis
  • FIG. 4 Porter's Five Forces Analysis: Global Hospital Acquired Pneumonia Market
  • FIG. 5 Revenue trend of major branded drugs and vaccines in nosocomial pneumonia market (USD Million)
  • FIG. 6 Global Tedizolid Phosphate Market Revenue, 2017 - 2020 (USD Million)
  • FIG. 7 Global Ceftolozane/Tazobactam Market Revenue, 2017 - 2020 (USD million)
  • FIG. 8 Global Ceftazidime/Avibactam Market Revenue, 2017 - 2020 (USD Million)
  • FIG. 9 Global Amikacin Inhale Market Revenue, 2016 - 2020 (USD Million)
  • FIG. 10 Global Plazomicin Market Revenue, 2017 - 2020 (USD Million)
  • FIG. 11 Global Synflorix Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 12 AstraZeneca PLC: Annual Revenue, 2011 - 2013 (USD Million)
  • FIG. 13 Cubist Pharmaceuticals, Inc.: Annual Revenue, 2011 - 2013 (USD Million)
  • FIG. 14 Meiji Holdings, Co. Ltd., Pharmaceutical Segment.: Annual Revenue, 2011 - 2013 (USD Million)
  • FIG. 15 Merck & Co. Inc.: Annual Revenue, 2011 - 2013 (USD Million)
  • FIG. 16 Sanofi: Annual Revenue, 2011 - 2013 (USD Million)
  • FIG. 17 GlaxoSmithKline, Inc.: Annual Revenue, 2011 - 2013 (USD Million)

List of Tables

  • TABLE 1 Nosocomial Pneumonia Drugs and Vaccines, Market Snapshot
  • TABLE 2 Investigational Candidates for Nosocomial Pneumonia Treatment
  • TABLE 3 Prevalence of Hospital Acquired Infections in Developed and Developing Countries
  • TABLE 4 Event Impact Analysis, Hospital Acquired Pneumonia Market
Back to Top